Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Nicholas Galakatos. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Nicholas Galakatos har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:ETTX / Entasis Therapeutics Holdings Inc | Director | 7.500 |
US:NSTG / NanoString Technologies, Inc. | Director, 10% Owner | 4.410 |
US:FTSV / Forty Seven, Inc. | 10% Owner | 0 |
US:HAIR / Restoration Robotics, Inc. | 10% Owner | 0 |
US:RDUS / Radius Recycling, Inc. | 2.459.804 | |
US:CATB / Astria Therapeutics Inc | Director | 6.500 |
US:TLOG / TetraLogic Pharmaceuticals Corporation | 10% Owner | 2.214.523 |
US:SIEN / Sientra, Inc. | 10% Owner | 5.461.530 |
US:OPHT / Ophthotech Corp | Director | 3.945 |
10% Owner | 2.237.377 | |
US:AERI / Aerie Pharmaceuticals Inc | 10% Owner | 0 |
Director | 10.000 | |
US:GMED / Globus Medical, Inc. | 0 | |
US:KBIO / KaloBios Pharmaceuticals, Inc. | 10% Owner | 0 |
US:SOMX / Somaxon Pharmaceuticals, Inc. | 10% Owner | 1.275.886 |
10% Owner | 3 | |
US:ZGNX / Zogenix Inc | 10% Owner | 9.482.439 |
US:AVNR / Avanir Pharmaceuticals Inc | 10% Owner | 12 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Nicholas Galakatos. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ATXS / Astria Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATXS / Astria Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ATXS / Astria Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATXS / Astria Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TLOG / TetraLogic Pharmaceuticals Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATXS / Astria Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2013-12-17 | TLOG | Clarus Lifesciences II, L.P. | 1.425.063 | 7,0000 | 1.425.063 | 7,0000 | 9.975.441 | 31 | 12.25 | 7.481.581 | 75,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TLOG / TetraLogic Pharmaceuticals Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATXS / Astria Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VERO / Venus Concept Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATXS / Astria Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VERO / Venus Concept Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATXS / Astria Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Nicholas Galakatos som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-06-21 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Stock Option (Right to Buy) |
A - Award | 7.500 | 7.500 | |||||
2019-03-27 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
A - Award | 4.410 | 4.410 | |||||
2019-01-22 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Stock Option (right to buy) |
A - Award | 15.000 | 15.000 | |||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Series B-1 Tranche B Convertible Preferred Stock |
C - Conversion | -8.552.024 | 0 | -100,00 | ||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Series B-1 Tranche A Convertible Preferred Stock |
C - Conversion | -6.702.213 | 0 | -100,00 | ||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Series B Convertible Preferred Stock |
C - Conversion | -7.500.000 | 0 | -100,00 | ||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Common Stock |
P - Purchase | 453.395 | 1.623.405 | 38,75 | 15,00 | 6.800.925 | 24.351.075 | |
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Common Stock |
C - Conversion | 412.583 | 1.170.010 | 54,47 | ||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Common Stock |
C - Conversion | 323.341 | 685.170 | 89,36 | ||||
2018-10-02 |
|
4 | ETTX |
Entasis Therapeutics Holdings Inc.
Common Stock |
C - Conversion | 361.829 | 361.829 | |||||
2018-09-19 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock Warrant (Right to Buy) |
X - Other | -162.408 | 0 | -100,00 | ||||
2018-09-19 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
S - Sale | -85.823 | 4.036.025 | -2,08 | 15,99 | -1.372.310 | 64.536.040 | |
2018-09-19 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
X - Other | 162.408 | 4.121.848 | 4,10 | 8,45 | 1.372.023 | 34.821.372 | |
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Series B Preferred Stock |
C - Conversion | -1.922.682 | 0 | -100,00 | ||||
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Series A-2 Preferred Stock |
C - Conversion | -755.780 | 0 | -100,00 | ||||
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Series A-1 Preferred Stock |
C - Conversion | -938.489 | 0 | -100,00 | ||||
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Common Stock |
P - Purchase | 200.000 | 3.816.951 | 5,53 | 16,00 | 3.200.000 | 61.071.216 | |
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Common Stock |
C - Conversion | 1.922.682 | 3.616.951 | 113,48 | ||||
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Common Stock |
C - Conversion | 755.780 | 1.694.269 | 80,53 | ||||
2018-07-02 |
|
4 | FTSV |
Forty Seven, Inc.
Common Stock |
C - Conversion | 938.489 | 938.489 | |||||
2018-01-03 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
A - Award | 10.168 | 10.168 | |||||
2017-10-17 |
|
4 | HAIR |
Restoration Robotics Inc
Series C Preferred Stock |
C - Conversion | -3.389.105 | 0 | -100,00 | ||||
2017-10-17 |
|
4 | HAIR |
Restoration Robotics Inc
Convertible Promissory Note |
C - Conversion | 0 | ||||||
2017-10-17 |
|
4 | HAIR |
Restoration Robotics Inc
Common Stock |
C - Conversion | 180.881 | 3.569.986 | 5,34 | 7,00 | 1.266.167 | 24.989.902 | |
2017-10-17 |
|
4 | HAIR |
Restoration Robotics Inc
Common Stock |
C - Conversion | 3.389.105 | 3.389.105 | |||||
2017-10-13 |
|
4 | HAIR |
Restoration Robotics Inc
Convertible Promissory Note |
J - Other | 1.259.269,79 | ||||||
2017-01-04 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 8.611 | 8.611 | |||||
2016-09-29 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
J - Other | -1.229.902 | 2.459.804 | -33,33 | ||||
2016-08-05 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 6.500 | 6.500 | |||||
2016-02-10 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -230.507 | 2.214.523 | -9,43 | 0,16 | -36.881 | 354.324 | |
2016-02-10 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -103.123 | 2.445.030 | -4,05 | 0,19 | -19.593 | 464.556 | |
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-09 | 3 | SIEN |
Sientra, Inc.
Common Stock |
5.461.530 | ||||||||
2016-02-05 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -832.881 | 2.548.153 | -24,63 | 0,20 | -166.576 | 509.631 | |
2016-02-05 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -500.026 | 3.381.034 | -12,88 | 0,14 | -70.004 | 473.345 | |
2016-02-05 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -82.583 | 3.881.060 | -2,08 | 0,15 | -12.387 | 582.159 | |
2016-02-02 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -176.306 | 3.963.643 | -4,26 | 0,17 | -29.972 | 673.819 | |
2016-02-02 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -140.000 | 4.139.949 | -3,27 | 0,20 | -28.000 | 827.990 | |
2016-02-02 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -52.826 | 4.279.949 | -1,22 | 0,26 | -13.735 | 1.112.787 | |
2016-01-28 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -32.521 | 4.332.775 | -0,74 | 0,26 | -8.455 | 1.126.522 | |
2016-01-28 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -209.984 | 4.365.296 | -4,59 | 0,27 | -56.696 | 1.178.630 | |
2016-01-28 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
S - Sale | -69.425 | 4.575.280 | -1,49 | 0,30 | -20.828 | 1.372.584 | |
2016-01-13 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -499 | 3.945 | -11,23 | 65,33 | -32.600 | 257.727 |
2016-01-13 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -501 | 4.444 | -10,13 | 65,45 | -32.790 | 290.860 |
2016-01-13 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.001 | 5.684 | -14,97 | 66,33 | -66.396 | 377.020 |
2016-01-13 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -999 | 6.685 | -13,00 | 65,45 | -65.385 | 437.533 |
2016-01-05 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 7.828 | 7.828 | |||||
2015-12-14 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -733 | 4.945 | -12,91 | 64,63 | -47.374 | 319.595 |
2015-12-14 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -267 | 5.678 | -4,49 | 63,91 | -17.064 | 362.881 |
2015-12-14 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.467 | 7.684 | -16,03 | 64,63 | -94.812 | 496.617 |
2015-12-14 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -533 | 9.151 | -5,50 | 63,90 | -34.059 | 584.749 |
2015-11-19 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -500 | 5.945 | -7,76 | 60,00 | -30.000 | 356.700 |
2015-11-19 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.000 | 9.684 | -9,36 | 60,00 | -60.000 | 581.040 |
2015-11-12 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -500 | 6.445 | -7,20 | 58,69 | -29.345 | 378.257 |
2015-11-12 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.000 | 10.684 | -8,56 | 58,69 | -58.690 | 627.044 |
2015-11-12 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -500 | 6.945 | -6,72 | 60,00 | -30.000 | 416.700 |
2015-11-12 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.000 | 11.684 | -7,88 | 60,00 | -60.000 | 701.040 |
2015-11-04 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -500 | 7.445 | -6,29 | 54,00 | -27.000 | 402.030 |
2015-11-04 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | X | -1.000 | 13.184 | -7,05 | 54,00 | -54.000 | 711.936 |
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 11.094 | 11.094 | |||||
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -9.728.971 | 0 | -100,00 | ||||
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -20.800.000 | 0 | -100,00 | ||||
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 376.695 | 2.752.488 | 15,86 | 12,00 | 4.520.340 | 33.029.856 | |
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 757.117 | 2.375.793 | 46,77 | ||||
2015-06-30 |
|
4 | CATB |
CATABASIS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.618.676 | 1.618.676 | |||||
2015-06-29 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
G - Gift | -1.020 | 14.184 | -6,71 | ||||
2015-06-17 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -39.701 | 2.237.377 | -1,74 | 14,30 | -567.724 | 31.994.491 | |
2015-06-17 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -1.529 | 2.277.078 | -0,07 | 14,27 | -21.819 | 32.493.903 | |
2015-06-12 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -6.430 | 2.278.607 | -0,28 | 14,25 | -91.628 | 32.470.150 | |
2015-06-12 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -25.168 | 2.285.037 | -1,09 | 14,27 | -359.147 | 32.607.478 | |
2015-06-10 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -8.987 | 2.310.205 | -0,39 | 14,32 | -128.694 | 33.082.136 | |
2015-06-10 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -13.000 | 2.319.192 | -0,56 | 14,26 | -185.380 | 33.071.678 | |
2015-06-10 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -2.662 | 2.332.192 | -0,11 | 14,25 | -37.934 | 33.233.736 | |
2015-06-08 |
|
4 | OPHT |
Ophthotech Corp.
Restricted Stock Units |
A - Award | 1.750 | 1.750 | |||||
2015-06-08 |
|
4 | OPHT |
Ophthotech Corp.
Stock Option (Right To Buy) |
A - Award | 7.000 | 7.000 | |||||
2015-06-03 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -10.450 | 2.334.854 | -0,45 | 14,32 | -149.644 | 33.435.109 | |
2015-06-03 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -11.014 | 2.345.304 | -0,47 | 14,25 | -156.950 | 33.420.582 | |
2015-06-03 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -15.010 | 2.356.318 | -0,63 | 14,29 | -214.493 | 33.671.784 | |
2015-05-28 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | -1.554.744 | 0 | -100,00 | ||||
2015-05-28 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | 3.137 | 7.945 | 65,25 | ||||
2015-05-28 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | 7.319 | 15.204 | 92,82 | ||||
2015-05-28 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | -1.554.744 | 0 | -100,00 | ||||
2015-03-24 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -26.300 | 2.371.328 | -1,10 | 14,44 | -379.772 | 34.241.976 | |
2015-03-24 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -27.115 | 2.397.628 | -1,12 | 14,53 | -393.981 | 34.837.535 | |
2015-03-19 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -50.012 | 2.424.743 | -2,02 | 14,61 | -730.675 | 35.425.495 | |
2015-03-19 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -25.000 | 2.474.755 | -1,00 | 14,68 | -367.000 | 36.329.403 | |
2015-03-19 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
S - Sale | -79.307 | 2.499.755 | -3,08 | 14,67 | -1.163.434 | 36.671.406 | |
2015-01-30 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
J - Other | -3.139.447 | 0 | -100,00 | ||||
2015-01-30 |
|
4/A | AERI |
AERIE PHARMACEUTICALS INC
Common Stock Warrant |
C - Conversion | 184.812 | 0 | -100,00 | ||||
2015-01-30 |
|
4/A | AERI |
AERIE PHARMACEUTICALS INC
Series B Preferred Warrant |
C - Conversion | -184.812 | 0 | -100,00 | ||||
2015-01-30 |
|
4/A | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 321.000 | 3.468.494 | 10,20 | 10,00 | 3.210.000 | 34.684.940 | |
2015-01-12 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -175.000 | 3.324.259 | -5,00 | 31,11 | -5.444.250 | 103.417.697 | |
2015-01-06 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -10.200 | 3.499.259 | -0,29 | 31,11 | -317.322 | 108.861.947 | |
2015-01-06 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -13.420 | 3.509.459 | -0,38 | 30,67 | -411.591 | 107.635.108 | |
2015-01-05 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 7.307 | 7.307 | |||||
2014-12-30 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -6.214 | 3.522.879 | -0,18 | 30,03 | -186.606 | 105.792.056 | |
2014-12-30 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -74.510 | 3.529.093 | -2,07 | 30,05 | -2.239.026 | 106.049.245 | |
2014-12-24 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -263 | 3.603.603 | -0,01 | 30,00 | -7.890 | 108.108.090 | |
2014-12-24 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
S - Sale | -49.441 | 3.603.866 | -1,35 | 30,36 | -1.501.029 | 109.413.372 | |
2014-07-01 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 10.000 | 10.000 | |||||
2014-06-18 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | 2.308 | 4.808 | 92,32 | 44,24 | 102.104 | 212.701 | |
2014-06-18 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | 5.385 | 7.885 | 215,40 | 44,24 | 238.227 | 348.825 | |
2014-06-18 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
J - Other | -1.143.844 | 1.554.744 | -42,39 | 44,24 | -50.602.515 | 68.780.320 | |
2014-06-16 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Option (right to buy) |
A - Award | 13.500 | 13.500 | |||||
2014-06-16 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -15.482 | 2.698.588 | -0,57 | 44,00 | -681.208 | 118.737.872 | |
2014-06-16 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -82.277 | 2.714.070 | -2,94 | 44,01 | -3.621.225 | 119.453.277 | |
2014-06-16 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -47.217 | 2.796.347 | -1,66 | 44,51 | -2.101.657 | 124.467.083 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -500 | 4.500 | -10,00 | 44,32 | -22.160 | 199.440 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -29.217 | 2.843.564 | -1,02 | 44,53 | -1.301.074 | 126.627.886 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -200 | 2.872.781 | -0,01 | 46,80 | -9.360 | 134.446.151 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -36.880 | 2.872.981 | -1,27 | 45,90 | -1.692.630 | 131.857.187 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -79.824 | 2.909.861 | -2,67 | 44,66 | -3.564.988 | 129.956.138 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -39.362 | 2.989.685 | -1,30 | 46,78 | -1.841.500 | 139.868.526 | |
2014-06-11 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
S - Sale | -25.697 | 3.029.047 | -0,84 | 46,02 | -1.182.463 | 139.383.415 | |
2014-06-11 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
S - Sale | -404 | 0 | -100,00 | 23,36 | -9.437 | ||
2014-06-11 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
S - Sale | -965 | 0 | -100,00 | 23,36 | -22.542 | ||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred |
C - Conversion | -91.175 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-3 Convertible Preferred Stock |
C - Conversion | -53.331 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -217.873 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -269.724 | 0 | -100,00 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
J - Other | 694.449 | 3.689.706 | 23,18 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 399.891 | 2.995.257 | 15,41 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 255.881 | 2.595.366 | 10,94 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 1.045.351 | 2.339.485 | 80,78 | ||||
2014-06-10 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock |
C - Conversion | 1.294.134 | 1.294.134 | |||||
2014-05-23 |
|
4 | OPHT |
Ophthotech Corp.
Director Stock Options (Right to Buy) |
A - Award | 15.000 | 15.000 | |||||
2014-03-27 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
J - Other | 404 | 404 | |||||
2014-03-27 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
J - Other | 965 | 965 | |||||
2014-01-03 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 5.847 | 5.847 | |||||
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Warrants |
X - Other | -23.282 | 0 | -100,00 | 6,40 | -149.056 | ||
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Convertible Notes |
C - Conversion | -853.416 | 0 | -100,00 | ||||
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Series C Convertible Preferred Stock |
C - Conversion | -2.342.944 | 0 | -100,00 | ||||
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
X - Other | 23.282 | 4.644.705 | 0,50 | 6,40 | 149.056 | 29.736.330 | |
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
C - Conversion | 853.416 | 4.621.423 | 22,65 | 7,00 | 5.973.912 | 32.349.961 | |
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
C - Conversion | 2.342.944 | 3.768.007 | 164,41 | ||||
2013-12-19 |
|
4 | TLOG |
TETRALOGIC PHARMACEUTICALS CORP
Common Stock |
P - Purchase | 1.425.063 | 1.425.063 | 7,00 | 9.975.441 | 9.975.441 | ||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Series G Preferred Ordinary Shares |
C - Conversion | -203.439 | 0 | -100,00 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Series F Preferred Ordinary Shares |
C - Conversion | -553.859 | 0 | -100,00 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Series E Preferred Ordinary Shares |
C - Conversion | -1.239.308 | 0 | -100,00 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
C - Conversion | -582.456 | 0 | -100,00 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
C - Conversion | 203.439 | 2.579.062 | 8,56 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
C - Conversion | 553.859 | 2.375.623 | 30,40 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
C - Conversion | 1.239.308 | 1.821.764 | 212,77 | ||||
2013-11-25 |
|
4 | OXFD |
Oxford Immunotec Global PLC
Ordinary Shares |
C - Conversion | 582.456 | 582.456 | |||||
2013-11-20 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
P - Purchase | 2.500 | 2.500 | 22,00 | 55.000 | 55.000 | ||
2013-11-20 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
P - Purchase | 2.500 | 2.500 | 22,00 | 55.000 | 55.000 | ||
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Convertible Notes |
C - Conversion | -420.222 | 0 | -100,00 | ||||
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Series B Warrants |
C - Conversion | -184.812 | 0 | -100,00 | ||||
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Series B Convertible Preferred Stock |
C - Conversion | -2.727.272 | 0 | -100,00 | ||||
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
P - Purchase | 321.000 | 3.653.306 | 9,63 | 10,00 | 3.210.000 | 36.533.060 | |
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 184.812 | 3.332.306 | 5,87 | 0,05 | 9.241 | 166.615 | |
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 420.222 | 3.147.494 | 15,41 | ||||
2013-10-28 |
|
4 | AERI |
AERIE PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2.727.272 | 2.727.272 | |||||
2013-10-25 |
|
4 | OPHT |
Ophthotech Corp.
Stock Option (Right to Buy) |
A - Award | 22.033 | 22.033 | |||||
2013-10-02 |
|
4 | OPHT |
Ophthotech Corp.
Series C Preferred Stock |
C - Conversion | -186.027 | 0 | -100,00 | ||||
2013-10-02 |
|
4 | OPHT |
Ophthotech Corp.
Series B Preferred Stock |
C - Conversion | -2.542.373 | 0 | -100,00 | ||||
2013-10-02 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
C - Conversion | 186.027 | 2.728.390 | 7,32 | ||||
2013-10-02 |
|
4 | OPHT |
Ophthotech Corp.
Common Stock |
C - Conversion | 2.542.373 | 2.542.373 | |||||
2013-09-04 |
|
4 | GMED |
GLOBUS MEDICAL INC
Class A Common Stock |
J - Other | -7.244.201 | 0 | -100,00 | ||||
2013-07-12 |
|
4 | NSTG |
NanoString Technologies Inc
Stock Option (Right to Buy) |
A - Award | 8.768 | 8.768 | |||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock Warrant (Right to Buy) |
C - Conversion | 162.408 | 162.408 | 8,45 | 1.372.348 | 1.372.348 | ||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Series D Preferred Warrant (Right to Buy) |
C - Conversion | -162.408 | 0 | -100,00 | 8,45 | -1.372.348 | ||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Series E Preferred Stock |
C - Conversion | -148.342 | 0 | -100,00 | ||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Series D Preferred Stock |
C - Conversion | -812.045 | 0 | -100,00 | ||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Series C Preferred Stock |
C - Conversion | -2.249.053 | 0 | -100,00 | ||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
A - Award | 750.000 | 3.959.440 | 23,37 | 10,00 | 7.500.000 | 39.594.400 | |
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
C - Conversion | 148.342 | 3.209.440 | 4,85 | ||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
C - Conversion | 812.045 | 3.061.098 | 36,11 | ||||
2013-07-01 |
|
4 | NSTG |
NanoString Technologies Inc
Common Stock |
C - Conversion | 2.249.053 | 2.249.053 | |||||
2013-06-07 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 14.101 | 14.101 | |||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -120.566 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -8.106 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -3.641 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -10.189 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -2.334 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -550.530 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -37.016 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -16.625 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -46.526 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -10.658 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -553.204 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -37.196 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -16.707 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -46.752 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series B Preferred Stock |
C - Conversion | -10.710 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -807.939 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -54.323 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -24.400 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -68.280 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Series A Preferred Stock |
C - Conversion | -15.642 | 0 | -100,00 | ||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
C - Conversion | 2.032.239 | 2.032.239 | |||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
C - Conversion | 136.641 | 136.641 | |||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
C - Conversion | 61.373 | 61.373 | |||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
C - Conversion | 171.747 | 171.747 | |||||
2013-05-30 |
|
4 | PTLA |
PORTOLA PHARMACEUTICALS INC
Common Stock |
C - Conversion | 39.344 | 39.344 | |||||
2013-04-30 |
|
4 | RDUS |
Radius Health, Inc.
Common Stock Warrant |
P - Purchase | 227.939 | 0 | -100,00 | 6,14 | 1.400.001 | ||
2013-04-30 |
|
4 | RDUS |
Radius Health, Inc.
Series B Convertible Preferred Stock |
P - Purchase | 91.175 | 0 | -100,00 | 61,42 | 5.599.968 | ||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series D Preferred Stock |
C - Conversion | -275.539 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -337.622 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Series B-2 Preferred Stock |
C - Conversion | -1.949.879 | 0 | -100,00 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 313.527 | 2.632.928 | 13,52 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 369.522 | 2.319.401 | 18,95 | ||||
2013-02-07 |
|
4 | KBIO |
KALOBIOS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.949.879 | 1.949.879 | |||||
2012-08-10 |
|
4 | GMED |
GLOBUS MEDICAL INC
Series E Preferred Stock |
C - Conversion | -7.444.168 | 0 | -100,00 | ||||
2012-08-10 |
|
4 | GMED |
GLOBUS MEDICAL INC
Class A Common Stock |
S - Sale | -804.232 | 7.244.201 | -9,99 | 11,16 | -8.975.229 | 80.845.283 | |
2012-08-10 |
|
4 | GMED |
GLOBUS MEDICAL INC
Class A Common Stock |
C - Conversion | 7.444.168 | 8.048.433 | 1.231,94 | ||||
2012-08-02 | 3 | GMED |
GLOBUS MEDICAL INC
Class A Common Stock |
604.265 | ||||||||
2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.624.574 | 1.275.886 | -56,01 | 0,31 | -498.744 | 391.697 | |
2012-07-10 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -671.217 | 2.900.460 | -18,79 | 0,29 | -195.324 | 844.034 | |
2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -98.210 | 3.571.677 | -2,68 | 0,29 | -28.481 | 1.035.786 | |
2012-07-05 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -80.348 | 3.669.887 | -2,14 | 0,29 | -23.301 | 1.064.267 | |
2012-07-02 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -19.500 | 3.750.235 | -0,52 | 0,29 | -5.655 | 1.087.568 | |
2012-06-21 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -12.000 | 3.759.735 | -0,32 | 0,29 | -3.480 | 1.090.323 | |
2012-06-19 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.450 | 3.781.735 | -0,04 | 0,29 | -420 | 1.096.703 | |
2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -8.400 | 3.783.185 | -0,22 | 0,29 | -2.436 | 1.097.124 | |
2012-06-07 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.555 | 3.791.585 | -0,77 | 0,29 | -8.571 | 1.099.560 | |
2012-06-06 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
J - Other | -10.942.468 | 3 | -100,00 | ||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock Warrant (right to buy) |
X - Other | -1.290.922 | 0 | -100,00 | ||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock Warrant (right to buy) |
X - Other | -1.706.426 | 0 | -100,00 | ||||
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -708.810 | 10.942.471 | -6,08 | 7,49 | -5.311.255 | 81.994.124 | |
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
S - Sale | -608.146 | 11.651.281 | -4,96 | 7,49 | -4.556.960 | 87.305.379 | |
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
X - Other | 1.706.426 | 12.259.427 | 16,17 | 3,11 | 5.311.251 | 38.157.467 | |
2012-06-04 |
|
4 | ACHN |
ACHILLION PHARMACEUTICALS INC
Common Stock |
X - Other | 1.290.922 | 10.553.001 | 13,94 | 3,53 | 4.556.955 | 37.252.094 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -29.850 | 3.821.140 | -0,78 | 0,30 | -8.955 | 1.146.342 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -51.007 | 3.850.990 | -1,31 | 0,30 | -15.302 | 1.155.297 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -15.300 | 3.901.997 | -0,39 | 0,30 | -4.622 | 1.178.793 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -293.015 | 3.917.297 | -6,96 | 0,30 | -87.904 | 1.175.189 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -135.250 | 4.210.312 | -3,11 | 0,30 | -40.629 | 1.264.778 | |
2012-06-04 |
|
4 | SOMX |
Somaxon Pharmaceuticals, Inc.
Common Stock |
S - Sale | -287.000 | 4.345.562 | -6,20 | 0,30 | -86.990 | 1.317.140 | |
2011-09-20 |
|
4 | ZGNX |
ZOGENIX, INC.
Common Stock |
P - Purchase | 3.500.000 | 9.482.439 | 58,50 | 2,00 | 7.000.000 | 18.964.878 | |
2010-12-07 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
J - Other | -6.669.204 | 12 | -100,00 | ||||
2010-11-10 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.200.000 | 6.669.216 | -15,25 | 4,81 | -5.773.920 | 32.089.600 | |
2010-11-10 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -44.626 | 7.869.216 | -0,56 | 5,10 | -227.593 | 40.133.002 | |
2010-11-05 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -332.572 | 7.913.842 | -4,03 | 4,80 | -1.597.377 | 38.010.975 | |
2010-11-05 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.400.106 | 8.246.414 | -14,51 | 4,52 | -6.332.539 | 37.297.706 | |
2010-11-02 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.290.871 | 9.646.520 | -11,80 | 4,49 | -5.800.400 | 43.345.673 | |
2010-11-02 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -2.478.142 | 10.937.391 | -18,47 | 5,36 | -13.273.424 | 58.582.854 | |
2010-11-02 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.424.947 | 13.415.533 | -9,60 | 5,06 | -7.215.647 | 67.933.576 | |
2010-10-12 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -311.000 | 14.840.480 | -2,05 | 3,52 | -1.093.445 | 52.177.644 | |
2010-10-12 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -240.838 | 15.151.480 | -1,56 | 3,47 | -836.792 | 52.643.817 | |
2010-07-15 |
|
4 | AVNR |
AVANIR PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -165.000 | 15.392.318 | -1,06 | 3,53 | -583.143 | 54.399.530 | |
2008-04-11 | 3 | AVNR |
AVANIR PHARMACEUTICALS
Class A Common Stock |
15.557.318 |